Saturday, December 3, 2022


Biotechnology News Magazine


Avacta Group Announces AffyXell Secures $7.3 Million In Series A Financing

Avacta Group notes the funds will be used to further develop its pipeline of next generation cell and gene therapies.

ARCH Venture Partners Announces New $1.85 Billion Fund to Create and Fund Early Stage Biotechnology Companies

ARCH Venture Partners will invest Fund XI in early-stage biotechnology companies working on infectious disease, mental health, immunology, oncology, neurology, manufacturing, clinical trials, anti-aging medicines, genomic and biological tools, data sciences, and ways of reimagining diagnostics and therapies.

Vaxess Technologies Awarded NSF and DARPA Funding for Development of mRNA-Based Single-Dose, Refrigeration-Free Vaccine Patch

Vaxess Technologies developers of the MIMIX™ smart release patch, was awarded a grant from the National Science Foundation.

Innodem Neurosciences Receives $6 Mil US Dollars of Financing From Morningside Group

The company reports their mobile software technology is embodied in an application that turns a tablet or a smartphone into a device capable of capturing Eye Movement Biomarkers and Gaze Mapping Biomarkers accurately within minutes in order to assist a clinician's diagnosis.